need a new car? rent to own cars no credit check ...
May 26, 2026
7:33 am
explore the 2025 jeep compas: adventure awaits!...
May 26, 2026
7:38 am
Eli Lilly’s VERVE-102 Gene Editing Therapy Shows Promise as a One-Time Treatment for High Cholesterol
May 26, 2026
07:42
Eli Lilly and Company recently presented groundbreaking data from its Phase 1b Heart-2 study, demonstrating that a single dose of VERVE-102 could transform how we treat severe cholesterol disorders. Unveiled at the European Atherosclerosis Society (EAS) Congress and simultaneously published in The New England Journal of Medicine, the findings offer a glimpse into a future where cardiovascular care shifts from daily pills to a one-time genetic edit.
VERVE-102 is an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver. People with naturally occurring mutations that turn off this specific gene have low LDL-C (low-density lipoprotein cholesterol) for life and are remarkably protected against heart attacks. VERVE-102 aims to mimic this natural protective effect.
The treatment works by delivering a messenger RNA (mRNA) and a guide RNA encapsulated within a specialized lipid nanoparticle directly to the liver. Instead of making large cuts in the DNA double helix, this base-editing approach changes just a single letter in the genetic code, turning off the targeted gene without breaking the DNA strand.
Recent Posts
drive into the future with the 2025 subaru forester...
May 26, 2026
7:41 am
celebrate the holidays in a new hyundai palisade...
May 26, 2026
7:34 am
2025 jeep wrangler price one might not want to miss!...
May 26, 2026
7:38 am
want an suv with easy access and comfort for seniors? here’s how to get it!...
May 26, 2026
7:15 am
The ongoing Heart-2 trial is evaluating VERVE-102 in adults diagnosed with heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease (CAD)—conditions that cause lifelong elevations in “bad” cholesterol.
In an interim analysis of 35 participants given a single intravenous infusion, VERVE-102 yielded dramatic, dose-dependent reductions in both the PCSK9 protein and LDL-C levels:
| Dose Level (mg/kg) | Reduction in PCSK9 Protein | Reduction in LDL-C |
| 0.3 | 51% | 9% |
| 0.6 | – | 45% |
| 0.8 | – | 51% |
| 1.0 (Highest) | 88% | 62% |
Crucially, these reductions were not fleeting. Lilly reported that the cholesterol-lowering effects were sustained for up to 18 months following treatment.
Recent Posts
explore surprisingly affordable luxury ram 1500...
May 26, 2026
7:15 am
need a new car? rent to own cars no credit check ...
May 26, 2026
7:39 am
explore the 2025 jeep compas: adventure awaits!...
May 26, 2026
7:35 am
drive into the future with the 2025 subaru forester...
May 26, 2026
7:21 am
High cholesterol is an undisputed driver of coronary artery disease, which affects over 300 million people worldwide and remains a leading cause of death. Currently, patients rely on chronic, daily medications like statins or frequent injections to manage their lipid levels. Unfortunately, real-world adherence to these regimens is notoriously poor.
“Many patients with elevated LDL-C struggle to achieve sustained control despite ongoing efforts with the medicines available today,” noted Riyaz S. Patel, M.D., a cardiologist at Barts Health NHS Trust. “The need for new approaches is real.”
By offering a “one-and-done” treatment, VERVE-102 bypasses the hurdle of patient adherence entirely.
Safety is a critical hurdle for any genetic medicine. The Heart-2 trial data indicated that VERVE-102 was generally well-tolerated across all tested dose levels. There were no treatment-related serious adverse events or dose-limiting toxicities. The reported side effects were primarily mild, such as low-grade infusion-related reactions and fatigue.
Armed with these positive results, Eli Lilly plans to move forward aggressively. The U.S. Food and Drug Administration (FDA) has already granted VERVE-102 Fast Track designation, and Lilly expects to begin enrolling patients for a Phase 2 clinical study by the end of 2026.
Recent Posts
Garmin has officially entered the screen-free fitness tracking space with its latest release: the Cirqa Smart Band. Just as the Oura Ring triggered a wave of smart ring competitors, Whoop is now facing its own...
July 22, 2026
7:12 pm
celebrate the holidays in a new hyundai palisade...
July 22, 2026
6:46 pm
Serving the nation under the Agnipath scheme is a proud milestone, but what happens when the four-year tenure comes to an end? As the first batch of Agniveers prepares to complete their service on December...
July 22, 2026
6:31 pm
2025 jeep wrangler price one might not want to miss!...
July 22, 2026
6:01 pm
The United States has approved a landmark 30-year civil nuclear cooperation agreement with Saudi Arabia, marking one of the biggest shifts in U.S. nuclear policy in the Middle East in years. While the agreement is...
July 22, 2026
11:40 am
want an suv with easy access and comfort for seniors? here’s how to get it!...
July 22, 2026
11:18 am
Astronomers have uncovered new evidence suggesting that the Milky Way underwent a dramatic transformation around 10 billion years ago, when a violent collision with a dwarf galaxy caused the entire galactic disc to tilt by...
July 22, 2026
11:31 am
explore surprisingly affordable luxury ram 1500...
July 22, 2026
11:22 am
The wreckage of a Pan American Airways passenger plane that disappeared into the Atlantic Ocean after crashing off Puerto Rico in 1952 has been located more than seven decades later, bringing closure to one of...
July 22, 2026
11:05 am
need a new car? rent to own cars no credit check ...
July 22, 2026
10:59 am
Pakistan has reportedly asked the United States for a $10 billion currency support facility, hoping its recent diplomatic role in facilitating communication during the Iran conflict will pave the way for stronger economic cooperation with...
July 22, 2026
11:03 am
explore the 2025 jeep compas: adventure awaits!...
July 22, 2026
10:50 am